A Phase 2 Single-arm Study to Evaluate Safety and Efficacy of CRS-207 With Pembrolizumab in Adults With Previously-Treated Malignant Pleural Mesothelioma
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs CRS 207 (Primary) ; Pembrolizumab
- Indications Mesothelioma
- Focus Therapeutic Use
- Sponsors Aduro BioTech
- 28 Jun 2017 According to an Aduro BioTech media release, first patients has been dosed.
- 02 Jun 2017 Status changed from planning to recruiting.
- 17 May 2017 According to an Aduro BioTech media release, this trial will be conducted by Aduro BioTech in collaboration with Merck.